Company news
Poltreg Spolka Akcyjna (GPW:PTG) news
Poltreg Spolka Akcyjna news releases on 6ix. Latest, Mar 10, 2026: PolTREG moves forward with the European registration process for TREG therapy in type 1…
Press releases & updates
PolTREG moves forward with the European registration process for TREG therapy in type 1 diabetes
March 10, 2026
PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007
August 4, 2025
PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial
July 31, 2025
PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy
June 13, 2025
Positive EMA Opinion on Pediatric Investigation Plan for PolTREG’s Treg Therapy in Type 1 Diabetes
May 15, 2025
PolTREG launches Phase 2 cell therapy trial in children with presymptomatic diabetes
October 24, 2024
PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
September 26, 2024
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
September 16, 2024
PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence
September 9, 2024
PolTREG’s type-1 diabetes Treg cell therapy PTG-007 demonstrates long-term safety and efficacy for up to 12 years
June 24, 2024
PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximab
April 4, 2024
PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Poland
March 11, 2024
PolTREG appoints Dan Shelly as Chief Business Development Officer
February 21, 2024
PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy
January 30, 2024
PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes
January 16, 2024